Evidence map›Paper›PMID 42660113›Full record

ArticleCell reports. Medicine2026

RET-driven osteoprotegerin expression links medullary thyroid cancer to osteoblastic bone metastases.

Rozita Bagheri-Yarmand, Gabriel M Pagnotti, Joseph L Kidd, David Avila Ramirez, Trupti Trivedi, Leah Guerra, Zhongya Wang, Lucia Martinez Cruz, Jade M Moehle, Yaashmin S Jebaraj and 8 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cell reports. Medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors.

Rozita Bagheri-YarmandDepartment of Endocrine Neoplasia and Hormonal Disorders, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Gabriel M PagnottiDepartment of Endocrine Neoplasia and Hormonal Disorders, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Joseph L KiddDepartment of Endocrine Neoplasia and Hormonal Disorders, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
David Avila RamirezDepartment of Endocrine Neoplasia and Hormonal Disorders, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Trupti TrivediDepartment of Endocrine Neoplasia and Hormonal Disorders, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Leah GuerraDepartment of Endocrine Neoplasia and Hormonal Disorders, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Zhongya WangDepartment of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Lucia Martinez CruzDepartment of Endocrine Neoplasia and Hormonal Disorders, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Jade M MoehleDepartment of Endocrine Neoplasia and Hormonal Disorders, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Yaashmin S JebarajDepartment of Endocrine Neoplasia and Hormonal Disorders, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Xinhai WanDepartment of Endocrine Neoplasia and Hormonal Disorders, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Jian H SongGenitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Roland L BassettDepartment of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Sue-Hwa LinTranslational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Mimi I HuDepartment of Endocrine Neoplasia and Hormonal Disorders, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Steven I ShermanDepartment of Endocrine Neoplasia and Hormonal Disorders, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Marie-Claude HofmannDepartment of Endocrine Neoplasia and Hormonal Disorders, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Theresa A GuiseDepartment of Endocrine Neoplasia and Hormonal Disorders, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA. Electronic address: taguise@mdanderson.org.

Funding

Tumor Evolution and Metastasis ProgramP30CA016672 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI DIANE BODURKA · 1985 to 2026
$290.8M
NCI NIH HHS P30 CA016672
6 · The paper itself

Abstract

Development of bone metastases increases mortality in patients with medullary thyroid cancer (MTC), with ∼50% survival at 5 years after diagnosis, but the underlying mechanisms of action are unknown. We show that patient-derived MTC cells (RET

Indexed as

Bone NeoplasmsCarcinoma, NeuroendocrineOsteoblastsOsteoprotegerinProto-Oncogene Proteins c-retThyroid NeoplasmsAnimalsCell DifferentiationCell Line, TumorFemaleGene Expression Regulation, NeoplasticHumansMaleMiceOsteoclastsOsteoprotegerinProto-Oncogene Proteins c-retRET protein, humanbone metastasesmedullary thyroid cancerosteoblastic lesionsosteoprotegerinRETselpercatinibtyrosine kinase inhibitor

Identifiers

PMID42660113
PMCPMC13589480

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.